ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Immune Checkpoint Blockers Market Research Report 2025
Published Date: April 2025
|
Report Code: QYRE-Auto-35V8512
Home | Market Reports | Business & Industrial| Pharmaceuticals & Biotech
Global Immune Checkpoint Blockers Market Insights Forecast to 2028
BUY CHAPTERS

Global Immune Checkpoint Blockers Market Research Report 2025

Code: QYRE-Auto-35V8512
Report
April 2025
Pages:86
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
Bristol–Myers Squibb
Merck
Astrazeneca plc
Roche
Sanofi
AbbVie

Immune Checkpoint Blockers Market Size

The global market for Immune Checkpoint Blockers was valued at US$ 24390 million in the year 2024 and is projected to reach a revised size of US$ 72040 million by 2031, growing at a CAGR of 17.0% during the forecast period.

Immune Checkpoint Blockers Market

Immune Checkpoint Blockers Market

Immune Checkpoint Blockers are a class of drugs that enhance the immune system's ability to target tumors by inhibiting the action of negative regulatory molecules within the immune system. Immune checkpoints are molecules on the surface of immune cells that normally limit immune responses to prevent damage to the body's own tissues. However, tumor cells often exploit these checkpoints to evade immune surveillance, thus promoting tumor growth and spread.
Immune checkpoint blockers work by blocking these checkpoint receptors (such as PD-1, CTLA-4, etc.), removing the suppression on the immune system and restoring immune cells' anti-tumor functions. The most common immune checkpoint blockers include anti-PD-1 antibodies (such as nivolumab, pembrolizumab) and anti-CTLA-4 antibodies (such as ipilimumab). These drugs have shown significant effectiveness in treating various cancers, such as melanoma, non-small cell lung cancer, and renal cell carcinoma.
Immune checkpoint blockers provide new treatment options for patients with advanced cancers, especially when traditional treatments are ineffective, significantly improving patient survival rates. They represent a major advancement in immunotherapy, changing the landscape of cancer treatment and offering new hope for the future of cancer therapy.
Market Development Opportunities and Key Drivers
The immune checkpoint blockers market is growing rapidly, driven by several key factors. First, there is an increasing demand for new treatment options as traditional therapies become less effective, especially for advanced cancers. Immune checkpoint blockers have shown significant efficacy across various cancer types, leading to expanding market demand. Second, ongoing innovation in drug development is introducing more immune checkpoint blockers into clinical use, providing more treatment options. Additionally, the rising global cancer incidence and aging population are further driving market growth.
Market Risks
The immune checkpoint blockers market also faces several challenges. First, the high cost of treatment may limit access in certain regions or among specific populations. Second, some patients may experience immune-related side effects or develop resistance to the therapy, which can affect treatment efficacy and continuity. Moreover, as more competitors enter the market, including the emergence of new immunotherapies, competition may intensify, requiring companies to maintain an edge in innovation and efficacy.
Downstream Demand Trends
In the future, demand for immune checkpoint blockers will be driven by the rise of personalized treatment and combination therapy models. Personalized treatment can tailor therapy based on a patient's genetic and tumor characteristics, improving treatment outcomes. Additionally, the trend of combining immune checkpoint blockers with other therapies (such as chemotherapy and targeted drugs) is increasing, creating new growth opportunities in the market. With advancements in early cancer diagnosis technology, the application of immune checkpoint blockers may expand to early-stage cancer treatments as well.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Immune Checkpoint Blockers, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Immune Checkpoint Blockers.
The Immune Checkpoint Blockers market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Immune Checkpoint Blockers market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Immune Checkpoint Blockers manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Scope of Immune Checkpoint Blockers Market Report

Report Metric Details
Report Name Immune Checkpoint Blockers Market
Accounted market size in year US$ 24390 million
Forecasted market size in 2031 US$ 72040 million
CAGR 17.0%
Base Year year
Forecasted years 2025 - 2031
Segment by Type
  • Anti-PD-L1 Drug
  • Anti-PD-1 Drug
  • CTLA4
Segment by Application
Consumption by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, Taiwan)
  • Southeast Asia (India)
  • Latin America (Mexico, Brazil)
By Company Sanofi, AbbVie, Bristol Myers Squibb, Merck, AstraZeneca, Roche
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Core Chapters

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Detailed analysis of Immune Checkpoint Blockers manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 3: Sales, revenue of Immune Checkpoint Blockers in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
  • Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
  • Chapter 9: The main points and conclusions of the report. 

FAQ for this report

How fast is Immune Checkpoint Blockers Market growing?

Ans: The Immune Checkpoint Blockers Market witnessing a CAGR of 17.0% during the forecast period 2025-2031.

What is the Immune Checkpoint Blockers Market size in 2031?

Ans: The Immune Checkpoint Blockers Market size in 2031 will be US$ 72040 million.

Who are the main players in the Immune Checkpoint Blockers Market report?

Ans: The main players in the Immune Checkpoint Blockers Market are Sanofi, AbbVie, Bristol Myers Squibb, Merck, AstraZeneca, Roche

What are the Application segmentation covered in the Immune Checkpoint Blockers Market report?

Ans: The Applications covered in the Immune Checkpoint Blockers Market report are Lung Cancer, Colorectal Cancer, BreastCancer, Prostate Cancer, Melanoma, Blood Cancers

What are the Type segmentation covered in the Immune Checkpoint Blockers Market report?

Ans: The Types covered in the Immune Checkpoint Blockers Market report are Anti-PD-L1 Drug, Anti-PD-1 Drug, CTLA4

Recommended Reports

Immune Checkpoint Inhibitors

Cancer Immunotherapy Drugs

Cellular Immunotherapies

1 Immune Checkpoint Blockers Market Overview
1.1 Product Definition
1.2 Immune Checkpoint Blockers by Type
1.2.1 Global Immune Checkpoint Blockers Market Value Comparison by Type (2024 VS 2031)
1.2.2 Anti-PD-L1 Drug
1.2.3 Anti-PD-1 Drug
1.2.4 CTLA4
1.3 Immune Checkpoint Blockers by Application
1.3.1 Global Immune Checkpoint Blockers Market Value by Application (2024 VS 2031)
1.3.2 Lung Cancer
1.3.3 Colorectal Cancer
1.3.4 BreastCancer
1.3.5 Prostate Cancer
1.3.6 Melanoma
1.3.7 Blood Cancers
1.4 Global Immune Checkpoint Blockers Market Size Estimates and Forecasts
1.4.1 Global Immune Checkpoint Blockers Revenue 2020-2031
1.4.2 Global Immune Checkpoint Blockers Sales 2020-2031
1.4.3 Global Immune Checkpoint Blockers Market Average Price (2020-2031)
1.5 Assumptions and Limitations
2 Immune Checkpoint Blockers Market Competition by Manufacturers
2.1 Global Immune Checkpoint Blockers Sales Market Share by Manufacturers (2020-2025)
2.2 Global Immune Checkpoint Blockers Revenue Market Share by Manufacturers (2020-2025)
2.3 Global Immune Checkpoint Blockers Average Price by Manufacturers (2020-2025)
2.4 Global Key Players of Immune Checkpoint Blockers, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Immune Checkpoint Blockers, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Immune Checkpoint Blockers, Product Type & Application
2.7 Global Key Manufacturers of Immune Checkpoint Blockers, Date of Enter into This Industry
2.8 Global Immune Checkpoint Blockers Market Competitive Situation and Trends
2.8.1 Global Immune Checkpoint Blockers Market Concentration Rate
2.8.2 The Global 5 and 10 Largest Immune Checkpoint Blockers Players Market Share by Revenue
2.8.3 Global Immune Checkpoint Blockers Company Type and Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Immune Checkpoint Blockers Market Scenario by Region
3.1 Global Immune Checkpoint Blockers Market Size by Region: 2020 Versus 2024 Versus 2031
3.2 Global Immune Checkpoint Blockers Sales by Region: 2020-2031
3.2.1 Global Immune Checkpoint Blockers Sales by Region: 2020-2025
3.2.2 Global Immune Checkpoint Blockers Sales by Region: 2026-2031
3.3 Global Immune Checkpoint Blockers Revenue by Region: 2020-2031
3.3.1 Global Immune Checkpoint Blockers Revenue by Region: 2020-2025
3.3.2 Global Immune Checkpoint Blockers Revenue by Region: 2026-2031
3.4 North America Immune Checkpoint Blockers Market Facts & Figures by Country
3.4.1 North America Immune Checkpoint Blockers Market Size by Country: 2020 VS 2024 VS 2031
3.4.2 North America Immune Checkpoint Blockers Sales by Country (2020-2031)
3.4.3 North America Immune Checkpoint Blockers Revenue by Country (2020-2031)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Immune Checkpoint Blockers Market Facts & Figures by Country
3.5.1 Europe Immune Checkpoint Blockers Market Size by Country: 2020 VS 2024 VS 2031
3.5.2 Europe Immune Checkpoint Blockers Sales by Country (2020-2031)
3.5.3 Europe Immune Checkpoint Blockers Revenue by Country (2020-2031)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Immune Checkpoint Blockers Market Facts & Figures by Region
3.6.1 Asia Pacific Immune Checkpoint Blockers Market Size by Region: 2020 VS 2024 VS 2031
3.6.2 Asia Pacific Immune Checkpoint Blockers Sales by Region (2020-2031)
3.6.3 Asia Pacific Immune Checkpoint Blockers Revenue by Region (2020-2031)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Immune Checkpoint Blockers Market Facts & Figures by Country
3.7.1 Latin America Immune Checkpoint Blockers Market Size by Country: 2020 VS 2024 VS 2031
3.7.2 Latin America Immune Checkpoint Blockers Sales by Country (2020-2031)
3.7.3 Latin America Immune Checkpoint Blockers Revenue by Country (2020-2031)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Immune Checkpoint Blockers Market Facts & Figures by Country
3.8.1 Middle East and Africa Immune Checkpoint Blockers Market Size by Country: 2020 VS 2024 VS 2031
3.8.2 Middle East and Africa Immune Checkpoint Blockers Sales by Country (2020-2031)
3.8.3 Middle East and Africa Immune Checkpoint Blockers Revenue by Country (2020-2031)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 U.A.E
4 Segment by Type
4.1 Global Immune Checkpoint Blockers Sales by Type (2020-2031)
4.1.1 Global Immune Checkpoint Blockers Sales by Type (2020-2025)
4.1.2 Global Immune Checkpoint Blockers Sales by Type (2026-2031)
4.1.3 Global Immune Checkpoint Blockers Sales Market Share by Type (2020-2031)
4.2 Global Immune Checkpoint Blockers Revenue by Type (2020-2031)
4.2.1 Global Immune Checkpoint Blockers Revenue by Type (2020-2025)
4.2.2 Global Immune Checkpoint Blockers Revenue by Type (2026-2031)
4.2.3 Global Immune Checkpoint Blockers Revenue Market Share by Type (2020-2031)
4.3 Global Immune Checkpoint Blockers Price by Type (2020-2031)
5 Segment by Application
5.1 Global Immune Checkpoint Blockers Sales by Application (2020-2031)
5.1.1 Global Immune Checkpoint Blockers Sales by Application (2020-2025)
5.1.2 Global Immune Checkpoint Blockers Sales by Application (2026-2031)
5.1.3 Global Immune Checkpoint Blockers Sales Market Share by Application (2020-2031)
5.2 Global Immune Checkpoint Blockers Revenue by Application (2020-2031)
5.2.1 Global Immune Checkpoint Blockers Revenue by Application (2020-2025)
5.2.2 Global Immune Checkpoint Blockers Revenue by Application (2026-2031)
5.2.3 Global Immune Checkpoint Blockers Revenue Market Share by Application (2020-2031)
5.3 Global Immune Checkpoint Blockers Price by Application (2020-2031)
6 Key Companies Profiled
6.1 Sanofi
6.1.1 Sanofi Company Information
6.1.2 Sanofi Description and Business Overview
6.1.3 Sanofi Immune Checkpoint Blockers Sales, Revenue and Gross Margin (2020-2025)
6.1.4 Sanofi Immune Checkpoint Blockers Product Portfolio
6.1.5 Sanofi Recent Developments/Updates
6.2 AbbVie
6.2.1 AbbVie Company Information
6.2.2 AbbVie Description and Business Overview
6.2.3 AbbVie Immune Checkpoint Blockers Sales, Revenue and Gross Margin (2020-2025)
6.2.4 AbbVie Immune Checkpoint Blockers Product Portfolio
6.2.5 AbbVie Recent Developments/Updates
6.3 Bristol Myers Squibb
6.3.1 Bristol Myers Squibb Company Information
6.3.2 Bristol Myers Squibb Description and Business Overview
6.3.3 Bristol Myers Squibb Immune Checkpoint Blockers Sales, Revenue and Gross Margin (2020-2025)
6.3.4 Bristol Myers Squibb Immune Checkpoint Blockers Product Portfolio
6.3.5 Bristol Myers Squibb Recent Developments/Updates
6.4 Merck
6.4.1 Merck Company Information
6.4.2 Merck Description and Business Overview
6.4.3 Merck Immune Checkpoint Blockers Sales, Revenue and Gross Margin (2020-2025)
6.4.4 Merck Immune Checkpoint Blockers Product Portfolio
6.4.5 Merck Recent Developments/Updates
6.5 AstraZeneca
6.5.1 AstraZeneca Company Information
6.5.2 AstraZeneca Description and Business Overview
6.5.3 AstraZeneca Immune Checkpoint Blockers Sales, Revenue and Gross Margin (2020-2025)
6.5.4 AstraZeneca Immune Checkpoint Blockers Product Portfolio
6.5.5 AstraZeneca Recent Developments/Updates
6.6 Roche
6.6.1 Roche Company Information
6.6.2 Roche Description and Business Overview
6.6.3 Roche Immune Checkpoint Blockers Sales, Revenue and Gross Margin (2020-2025)
6.6.4 Roche Immune Checkpoint Blockers Product Portfolio
6.6.5 Roche Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Immune Checkpoint Blockers Industry Chain Analysis
7.2 Immune Checkpoint Blockers Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Immune Checkpoint Blockers Production Mode & Process Analysis
7.4 Immune Checkpoint Blockers Sales and Marketing
7.4.1 Immune Checkpoint Blockers Sales Channels
7.4.2 Immune Checkpoint Blockers Distributors
7.5 Immune Checkpoint Blockers Customer Analysis
8 Immune Checkpoint Blockers Market Dynamics
8.1 Immune Checkpoint Blockers Industry Trends
8.2 Immune Checkpoint Blockers Market Drivers
8.3 Immune Checkpoint Blockers Market Challenges
8.4 Immune Checkpoint Blockers Market Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
FEATURED COMPANIES
Bristol–Myers Squibb
Merck
Astrazeneca plc
Roche
Sanofi
AbbVie
List of Tables
 Table 1. Global Immune Checkpoint Blockers Market Value Comparison by Type (2024 VS 2031) & (US$ Million)
 Table 2. Global Immune Checkpoint Blockers Market Value by Application (2024 VS 2031) & (US$ Million)
 Table 3. Global Immune Checkpoint Blockers Market Competitive Situation by Manufacturers in 2024
 Table 4. Global Immune Checkpoint Blockers Sales (K Units) of Key Manufacturers (2020-2025)
 Table 5. Global Immune Checkpoint Blockers Sales Market Share by Manufacturers (2020-2025)
 Table 6. Global Immune Checkpoint Blockers Revenue (US$ Million) by Manufacturers (2020-2025)
 Table 7. Global Immune Checkpoint Blockers Revenue Share by Manufacturers (2020-2025)
 Table 8. Global Market Immune Checkpoint Blockers Average Price (USD/Unit) of Key Manufacturers (2020-2025)
 Table 9. Global Key Players of Immune Checkpoint Blockers, Industry Ranking, 2022 VS 2023 VS 2024
 Table 10. Global Key Manufacturers of Immune Checkpoint Blockers, Manufacturing Sites & Headquarters
 Table 11. Global Key Manufacturers of Immune Checkpoint Blockers, Product Type & Application
 Table 12. Global Key Manufacturers of Immune Checkpoint Blockers, Date of Enter into This Industry
 Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
 Table 14. Global Immune Checkpoint Blockers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Immune Checkpoint Blockers as of 2024)
 Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
 Table 16. Global Immune Checkpoint Blockers Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 17. Global Immune Checkpoint Blockers Sales by Region (2020-2025) & (K Units)
 Table 18. Global Immune Checkpoint Blockers Sales Market Share by Region (2020-2025)
 Table 19. Global Immune Checkpoint Blockers Sales by Region (2026-2031) & (K Units)
 Table 20. Global Immune Checkpoint Blockers Sales Market Share by Region (2026-2031)
 Table 21. Global Immune Checkpoint Blockers Revenue by Region (2020-2025) & (US$ Million)
 Table 22. Global Immune Checkpoint Blockers Revenue Market Share by Region (2020-2025)
 Table 23. Global Immune Checkpoint Blockers Revenue by Region (2026-2031) & (US$ Million)
 Table 24. Global Immune Checkpoint Blockers Revenue Market Share by Region (2026-2031)
 Table 25. North America Immune Checkpoint Blockers Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 26. North America Immune Checkpoint Blockers Sales by Country (2020-2025) & (K Units)
 Table 27. North America Immune Checkpoint Blockers Sales by Country (2026-2031) & (K Units)
 Table 28. North America Immune Checkpoint Blockers Revenue by Country (2020-2025) & (US$ Million)
 Table 29. North America Immune Checkpoint Blockers Revenue by Country (2026-2031) & (US$ Million)
 Table 30. Europe Immune Checkpoint Blockers Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 31. Europe Immune Checkpoint Blockers Sales by Country (2020-2025) & (K Units)
 Table 32. Europe Immune Checkpoint Blockers Sales by Country (2026-2031) & (K Units)
 Table 33. Europe Immune Checkpoint Blockers Revenue by Country (2020-2025) & (US$ Million)
 Table 34. Europe Immune Checkpoint Blockers Revenue by Country (2026-2031) & (US$ Million)
 Table 35. Asia Pacific Immune Checkpoint Blockers Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 36. Asia Pacific Immune Checkpoint Blockers Sales by Region (2020-2025) & (K Units)
 Table 37. Asia Pacific Immune Checkpoint Blockers Sales by Region (2026-2031) & (K Units)
 Table 38. Asia Pacific Immune Checkpoint Blockers Revenue by Region (2020-2025) & (US$ Million)
 Table 39. Asia Pacific Immune Checkpoint Blockers Revenue by Region (2026-2031) & (US$ Million)
 Table 40. Latin America Immune Checkpoint Blockers Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 41. Latin America Immune Checkpoint Blockers Sales by Country (2020-2025) & (K Units)
 Table 42. Latin America Immune Checkpoint Blockers Sales by Country (2026-2031) & (K Units)
 Table 43. Latin America Immune Checkpoint Blockers Revenue by Country (2020-2025) & (US$ Million)
 Table 44. Latin America Immune Checkpoint Blockers Revenue by Country (2026-2031) & (US$ Million)
 Table 45. Middle East and Africa Immune Checkpoint Blockers Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 46. Middle East and Africa Immune Checkpoint Blockers Sales by Country (2020-2025) & (K Units)
 Table 47. Middle East and Africa Immune Checkpoint Blockers Sales by Country (2026-2031) & (K Units)
 Table 48. Middle East and Africa Immune Checkpoint Blockers Revenue by Country (2020-2025) & (US$ Million)
 Table 49. Middle East and Africa Immune Checkpoint Blockers Revenue by Country (2026-2031) & (US$ Million)
 Table 50. Global Immune Checkpoint Blockers Sales (K Units) by Type (2020-2025)
 Table 51. Global Immune Checkpoint Blockers Sales (K Units) by Type (2026-2031)
 Table 52. Global Immune Checkpoint Blockers Sales Market Share by Type (2020-2025)
 Table 53. Global Immune Checkpoint Blockers Sales Market Share by Type (2026-2031)
 Table 54. Global Immune Checkpoint Blockers Revenue (US$ Million) by Type (2020-2025)
 Table 55. Global Immune Checkpoint Blockers Revenue (US$ Million) by Type (2026-2031)
 Table 56. Global Immune Checkpoint Blockers Revenue Market Share by Type (2020-2025)
 Table 57. Global Immune Checkpoint Blockers Revenue Market Share by Type (2026-2031)
 Table 58. Global Immune Checkpoint Blockers Price (USD/Unit) by Type (2020-2025)
 Table 59. Global Immune Checkpoint Blockers Price (USD/Unit) by Type (2026-2031)
 Table 60. Global Immune Checkpoint Blockers Sales (K Units) by Application (2020-2025)
 Table 61. Global Immune Checkpoint Blockers Sales (K Units) by Application (2026-2031)
 Table 62. Global Immune Checkpoint Blockers Sales Market Share by Application (2020-2025)
 Table 63. Global Immune Checkpoint Blockers Sales Market Share by Application (2026-2031)
 Table 64. Global Immune Checkpoint Blockers Revenue (US$ Million) by Application (2020-2025)
 Table 65. Global Immune Checkpoint Blockers Revenue (US$ Million) by Application (2026-2031)
 Table 66. Global Immune Checkpoint Blockers Revenue Market Share by Application (2020-2025)
 Table 67. Global Immune Checkpoint Blockers Revenue Market Share by Application (2026-2031)
 Table 68. Global Immune Checkpoint Blockers Price (USD/Unit) by Application (2020-2025)
 Table 69. Global Immune Checkpoint Blockers Price (USD/Unit) by Application (2026-2031)
 Table 70. Sanofi Company Information
 Table 71. Sanofi Description and Business Overview
 Table 72. Sanofi Immune Checkpoint Blockers Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 73. Sanofi Immune Checkpoint Blockers Product
 Table 74. Sanofi Recent Developments/Updates
 Table 75. AbbVie Company Information
 Table 76. AbbVie Description and Business Overview
 Table 77. AbbVie Immune Checkpoint Blockers Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 78. AbbVie Immune Checkpoint Blockers Product
 Table 79. AbbVie Recent Developments/Updates
 Table 80. Bristol Myers Squibb Company Information
 Table 81. Bristol Myers Squibb Description and Business Overview
 Table 82. Bristol Myers Squibb Immune Checkpoint Blockers Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 83. Bristol Myers Squibb Immune Checkpoint Blockers Product
 Table 84. Bristol Myers Squibb Recent Developments/Updates
 Table 85. Merck Company Information
 Table 86. Merck Description and Business Overview
 Table 87. Merck Immune Checkpoint Blockers Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 88. Merck Immune Checkpoint Blockers Product
 Table 89. Merck Recent Developments/Updates
 Table 90. AstraZeneca Company Information
 Table 91. AstraZeneca Description and Business Overview
 Table 92. AstraZeneca Immune Checkpoint Blockers Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 93. AstraZeneca Immune Checkpoint Blockers Product
 Table 94. AstraZeneca Recent Developments/Updates
 Table 95. Roche Company Information
 Table 96. Roche Description and Business Overview
 Table 97. Roche Immune Checkpoint Blockers Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 98. Roche Immune Checkpoint Blockers Product
 Table 99. Roche Recent Developments/Updates
 Table 100. Key Raw Materials Lists
 Table 101. Raw Materials Key Suppliers Lists
 Table 102. Immune Checkpoint Blockers Distributors List
 Table 103. Immune Checkpoint Blockers Customers List
 Table 104. Immune Checkpoint Blockers Market Trends
 Table 105. Immune Checkpoint Blockers Market Drivers
 Table 106. Immune Checkpoint Blockers Market Challenges
 Table 107. Immune Checkpoint Blockers Market Restraints
 Table 108. Research Programs/Design for This Report
 Table 109. Key Data Information from Secondary Sources
 Table 110. Key Data Information from Primary Sources
 Table 111. Authors List of This Report


List of Figures
 Figure 1. Product Picture of Immune Checkpoint Blockers
 Figure 2. Global Immune Checkpoint Blockers Market Value Comparison by Type (2020-2031) & (US$ Million)
 Figure 3. Global Immune Checkpoint Blockers Market Share by Type: 2024 & 2031
 Figure 4. Anti-PD-L1 Drug Product Picture
 Figure 5. Anti-PD-1 Drug Product Picture
 Figure 6. CTLA4 Product Picture
 Figure 7. Global Immune Checkpoint Blockers Market Value by Application (2020-2031) & (US$ Million)
 Figure 8. Global Immune Checkpoint Blockers Market Share by Application: 2024 & 2031
 Figure 9. Lung Cancer
 Figure 10. Colorectal Cancer
 Figure 11. BreastCancer
 Figure 12. Prostate Cancer
 Figure 13. Melanoma
 Figure 14. Blood Cancers
 Figure 15. Global Immune Checkpoint Blockers Revenue, (US$ Million), 2020 VS 2024 VS 2031
 Figure 16. Global Immune Checkpoint Blockers Market Size (2020-2031) & (US$ Million)
 Figure 17. Global Immune Checkpoint Blockers Sales (2020-2031) & (K Units)
 Figure 18. Global Immune Checkpoint Blockers Average Price (USD/Unit) & (2020-2031)
 Figure 19. Immune Checkpoint Blockers Report Years Considered
 Figure 20. Immune Checkpoint Blockers Sales Share by Manufacturers in 2024
 Figure 21. Global Immune Checkpoint Blockers Revenue Share by Manufacturers in 2024
 Figure 22. Global 5 and 10 Largest Immune Checkpoint Blockers Players: Market Share by Revenue in Immune Checkpoint Blockers in 2024
 Figure 23. Immune Checkpoint Blockers Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
 Figure 24. Global Immune Checkpoint Blockers Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Figure 25. North America Immune Checkpoint Blockers Sales Market Share by Country (2020-2031)
 Figure 26. North America Immune Checkpoint Blockers Revenue Market Share by Country (2020-2031)
 Figure 27. U.S. Immune Checkpoint Blockers Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 28. Canada Immune Checkpoint Blockers Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 29. Europe Immune Checkpoint Blockers Sales Market Share by Country (2020-2031)
 Figure 30. Europe Immune Checkpoint Blockers Revenue Market Share by Country (2020-2031)
 Figure 31. Germany Immune Checkpoint Blockers Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 32. France Immune Checkpoint Blockers Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 33. U.K. Immune Checkpoint Blockers Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 34. Italy Immune Checkpoint Blockers Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 35. Russia Immune Checkpoint Blockers Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 36. Asia Pacific Immune Checkpoint Blockers Sales Market Share by Region (2020-2031)
 Figure 37. Asia Pacific Immune Checkpoint Blockers Revenue Market Share by Region (2020-2031)
 Figure 38. China Immune Checkpoint Blockers Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 39. Japan Immune Checkpoint Blockers Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 40. South Korea Immune Checkpoint Blockers Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 41. India Immune Checkpoint Blockers Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 42. Australia Immune Checkpoint Blockers Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 43. Taiwan Immune Checkpoint Blockers Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 44. Indonesia Immune Checkpoint Blockers Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 45. Thailand Immune Checkpoint Blockers Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 46. Malaysia Immune Checkpoint Blockers Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 47. Philippines Immune Checkpoint Blockers Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 48. Latin America Immune Checkpoint Blockers Sales Market Share by Country (2020-2031)
 Figure 49. Latin America Immune Checkpoint Blockers Revenue Market Share by Country (2020-2031)
 Figure 50. Mexico Immune Checkpoint Blockers Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 51. Brazil Immune Checkpoint Blockers Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 52. Argentina Immune Checkpoint Blockers Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 53. Middle East and Africa Immune Checkpoint Blockers Sales Market Share by Country (2020-2031)
 Figure 54. Middle East and Africa Immune Checkpoint Blockers Revenue Market Share by Country (2020-2031)
 Figure 55. Turkey Immune Checkpoint Blockers Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 56. Saudi Arabia Immune Checkpoint Blockers Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 57. U.A.E Immune Checkpoint Blockers Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 58. Global Sales Market Share of Immune Checkpoint Blockers by Type (2020-2031)
 Figure 59. Global Revenue Market Share of Immune Checkpoint Blockers by Type (2020-2031)
 Figure 60. Global Immune Checkpoint Blockers Price (USD/Unit) by Type (2020-2031)
 Figure 61. Global Sales Market Share of Immune Checkpoint Blockers by Application (2020-2031)
 Figure 62. Global Revenue Market Share of Immune Checkpoint Blockers by Application (2020-2031)
 Figure 63. Global Immune Checkpoint Blockers Price (USD/Unit) by Application (2020-2031)
 Figure 64. Immune Checkpoint Blockers Value Chain
 Figure 65. Channels of Distribution (Direct Vs Distribution)
 Figure 66. Bottom-up and Top-down Approaches for This Report
 Figure 67. Data Triangulation
 Figure 68. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Nano Dimension

SIMILAR REPORTS

Global Immune Checkpoint Agents Market Research Report 2025
Global PD 1 Inhibitor Market Research Report 2024
Global Antibody Interference Blockers Market Insights Forecast to 2030
Global Checkpoint Inhibitor Refractory Cancer Market Research Report 2025
lmmune Checkpoint Inhibitors Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Immunoassay Interference Blocker Market Insights Forecast to 2030
Global PD 1 and PD L1 Monoclonal Antibody Market Research Report 2025
Global Pembrolizumab Market Research Report 2024
Global Tumor Immunity Therapy Market Research Report 2024
Global PD 1 and PD L1 Inhibitor Market Research Report 2025
Global Health Product for Immune Market Research Report 2024
Global Immune Adjuvant Market Research Report 2024
Global Avelumab Market Research Report 2024
Global Nivolumab Market Research Report 2024
Global Allergen Block Products Market Research Report 2024
Airborne Allergen Blocker Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Ad Blocker Market Research Report 2024
B Cell Receptor Inhibitor Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Allergy Immunotherapies Market Research Report 2025
Global DC Blocker Market Research Report 2024
Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions